Postmenopausal estrogen and progestin use in relation to breast cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 7, 2002, Pages 593-600

  Newcomb, Polly A ^a,b   Titus Ernstoff, Linda ^c   Egan, Kathleen M ^d   Trentham Dietz, Amy ^a   Baron, John A ^c   Storer, Barry E ^b   Willett, Walter C ^d,e   Stampfer, Meir J ^d,e  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HORMONAL THERAPY; HUMAN; INTERVIEW; INTRADUCTAL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UNITED STATES;

AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MASSACHUSETTS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PROBABILITY; PROGESTINS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WISCONSIN;

EID: 0036310161     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108,411 women without breast cancer
2. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies
3. Menopausal hormone replacement therapy and breast cancer: A meta-analysis
4. Hormone therapy to prevent disease and prolong life in postmenopausal women
5. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
6. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone
7. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement
8. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
9. Hormone replacement therapy in relation to breast cancer
10. Postmenopausal hormone use and risk of breast cancer by histologic type
11. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women
12. Pictorially assisted recall of past hormone use in case-control studies
13. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy
14. Hormonal contraceptives and postmenopausal hormone therapy
15. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women
16. Hormone replacement treatment and breast cancer risk: A cooperative Italian study
17. Breast cancer and cigarette smoking: A hypothesis
18. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women
19. Menopausal hormone usage and breast cancer in Saskatchewan: A record-linkage cohort study
20. Menopausal hormones and breast cancer in a biracial population
21. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark
22. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
23. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy
24. Menopausal oestrogens and breast cancer risk: An expanded case-control study
25. Type of postmenopausal hormone use and risk of breast cancer: 12-Year follow-up from the Nurses' Health Study
26. Increased risk of breast cancer with alcohol consumption in postmenopausal women
27. Risk of breast cancer in relation to lifetime alcohol consumption
28. Changing incidence rate of invasive lobular breast carcinoma among older women
29. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86
30. Sellers Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study
31. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
32. Postmenopausal estrogen and prevention bias
33. Prevalence and determinants of estrogen replacement therapy in elderly women
34. Reproductive factors and breast cancer
35. Estrogen levels in postmenopausal women with hot flashes
36. Plasma androstenedione and oestrone levels in the climacteric syndrome
37. Endogenous estrogen and postmenopausal breast cancer: A quantitative review
38. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer
39. Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial
40. Consistency of perimenopausal estrogen use reporting by women in a population-based prospective study
41. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports
42. Agreement between interview information and physician records on history of menopausal estrogen use
43. Participation rates in a case-control study: The impact of age, race, and race of interviewer
44. Noncontraceptive hormone use and risk of breast cancer
45. Physiological action of progesterone in target tissues
46. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture
47. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques
48. Structure function relationships, potency, and pharmacokinetics of progestogens
49. Progestins and antiprogestins in mammary tumour growth and metastasis
50. Role of 17β-hydroxysteroid dehydrogenase type I in endocrine and intracrine estradiol biosynthesis
51. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy
52. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors